�������ýҕ�l

A new UC San Diego study strengthens the growing body of evidence that marijuana use impacts adolescent brain development. Researchers observed slower gains in cognitive tests that measured memory, focus and thinking speed among middle and high school-age kids who used cannabis when compared to those who abstained. (Sisson, 4/21)

Britain aims to raise a “smoke-free generation” by permanently banning the sale or supply of tobacco and vape products to anyone born in 2009 or after, with a bill that was approved by Parliament on Tuesday. The bill applies to people currently 17 years old or younger and aims to keep them from ever picking up the habit in their lifetime. The proposal is expected to soon go into law after the final formality of approval by King Charles III. (Livni, 4/21)

A judge on Tuesday delayed the criminal sentencing of OxyContin maker Purdue Pharma in order to allow victims to attend the court proceeding in person. U.S. District Judge Madeline Cox Arleo originally planned to hand down the sentence Tuesday during a court hearing conducted only by videoconferencing. But she said she changed her mind after seeing some victims of the opioid crisis protesting outside her courthouse in Newark, New Jersey. She said they should be allowed to attend in person, too, and moved the hearing to next Tuesday. (Mulvihill, 4/22)

The FDA approved islatravir-doravirine (Idvynso) as a standalone, single-tablet regimen for treating HIV in virologically suppressed adults, Merck announced on Tuesday. Approval stipulates use of the oral combination in patients with HIV-1 who are virologically suppressed on stable antiretroviral therapy (ART), have no history of virologic treatment failure, and have no known substitutions associated with doravirine resistance. Co-administration with other ART medications is not recommended. (Rudd, 4/21)

The Swiss drugmaker Roche on Tuesday presented the latest data for its experimental multiple sclerosis drug, setting the stage for the company to seek approval for a medicine that it believes can cut relapse rates and slow the progressive disability the disease causes. (Joseph, 4/21)

A one-time, personalized cell therapy from Kyverna Therapeutics improved mobility and reduced disabilities in patients with stiff person syndrome, a rare, neurological autoimmune disorder, according to study results presented Tuesday. (Feuerstein, 4/21)

Amazon's One Medical is rolling out a national GLP-1 program as demand for weight-loss drugs surges, the company announced Tuesday. The boom in drugs like Ozempic and Wegovy is reshaping obesity care — but also exposing gaps in how patients are treated. (Tyko, 4/21)